Neurol. praxi. 2023;24(1):46-49 | DOI: 10.36290/neu.2023.003

The use of anti-CGRP monoclonal antibodies amongst wide variety of patients

MUDr. Markéta Škodová
Neurologické oddělení Nemocnice Jihlava, p. o.

Monoclonal CGRP antibodies represent a specific type of migraine profylaction. A high effectivity on both episodic and chronic migraine including concomitant medication overuse headache was proven in scientific studies as well as in clinical practice. Once-monthly or once-quarterly dosing improving the therapy adherence proved to be the main advantage of the treatment. The therapy is well tolerated by patients. Monoclonal CGRP antibodies do not affect the immune system and do not have drug interactions.

Keywords: monoclonal antibodies, CGRP, migraine, erenumab, fremanezumab, galcanezumab, eptinezumab.

Received: December 1, 2022; Revised: December 8, 2022; Accepted: January 9, 2023; Prepublished online: January 9, 2023; Published: March 3, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škodová M. The use of anti-CGRP monoclonal antibodies amongst wide variety of patients. Neurol. praxi. 2023;24(1):46-49. doi: 10.36290/neu.2023.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bártková A. Akutní a profylaktická terapie migrény. Prakt. lékaren. 2019;15(4):208-212.
    2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine‑current Understanding and treatment. N Engl J Med. 2002;346(4):257. Go to original source... Go to PubMed...
    3. Kojecký V. Anti­‑CGRP léčiva a trávicí trakt. Neurol. praxi. 2021;22(4):315-319. Go to original source...
    4. Nežádal T, Marková J, Bártková A, et al. CGRP monoklonální protilátky v léčbě migrény - indikační kritéria a terapeutická doporučení pro Českou republiku. Cesk Slov Neurol N. 2020;83/116(4):445-451. Go to original source...
    5. Nissan GR, Kim R, Cohen JM, et al. Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway­‑Targeted Preventive Treatments. J. Clin. Med. 2022;11:4359. Go to original source... Go to PubMed...
    6. Raffaelli B, Terhart M, Mecklenburg J, et al. Resumption of migraine preventive treatment with CGRP (-receptor) antibodies after a 3 month drug holiday: a real world experience. J Headache Pain. 2022;23:40. Go to original source... Go to PubMed...
    7. Souhrn údajů o přípravku Ajovy 225 mg 1 × 1,5 ml. 15. 10. 2022.
    8. Souhrn údajů o přípravku Aimovig 70 mg inj sol 1 × 1 ml. 15. 10. 2022.
    9. Souhrn údajů o přípravku Emgality 120 mg inj sol 1 × 1 ml. 15. 10. 2022.
    10. Souhrn údajů o přípravku Vyepti 100 mg 1 × 1 ml. 15. 10. 2022.
    11. Šípková J, Nežádal T, Čtrnáctá D, et al. Protilátky CGRP v profylaktické léčbě migrény. Cesk Slov Neurol N. 2022;85/118(3):248-256. Go to original source...
    12. Vernieri F, Brunelli N, Messina R, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one­‑year treatment: an observational longitudinalcohort study. J Headache Pain. 2021;22:154. Go to original source... Go to PubMed...
    13. Wen F, Yuhua Lv, Guomin Y, et al. Pilot study of amitriptyline in prophylactic treatment of medication­‑overuse headache: A 1-year follow­‑up. Pain Medicine. 2014 [cited 2022 Sep 8];15:1803-1810. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.